- HETEROCYCLIC COMPOUNDS FOR INHIBITING TYK2 ACTIVITIES
-
Provided are Compounds 1-8, and their pharmaceutically acceptable salts or prodrugs thereof. Compounds 1-8 are selective binders to TYK2's JH2 and they exhibit significant inhibitory effects on the physiological function of TYK2 and they have excellent in vivo pharmacokinetic properties. Compounds 1-5 and 7 have several deuterium substitutions on methyl to improve pharmacokinetic (PK) properties.
- -
-
Page/Page column 16-17
(2021/09/17)
-
- CRYSTALLINE FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE
-
Disclosed is crystalline Form B of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form B is the HCl salt of a neat crystalline form. Characterization data for Form B are disclosed.
- -
-
Page/Page column 19
(2019/12/25)
-
- PROCESS FOR THE PREPARATION OF 6-(CYCLOPROPANEAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE
-
The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
- -
-
Page/Page column 21-22
(2018/10/25)
-
- Synthesis and characterization of two formyl 2-tetrazenes
-
The synthesis of two formyl 2-tetrazenes, namely, (E)-1-formyl-1,4,4- trimethyl-2-tetrazene (2) and (E)-1,4-diformyl-1,4-dimethyl-2-tetrazene (3), by oxidation of (E)-1,1,4,4-tetramethyl-2-tetrazene (1) using potassium permanganate in acetone solution is presented. Compound 3 was also synthesized in an improved yield from the oxidation of 1-formyl-1-methylhydrazine (4 a) using potassium permanganate in acetone. Both compounds 2 and 3 were characterized by analytical (elemental analysis, GC-MS) and spectroscopic methods (1H, 13C, and 15N NMR spectroscopy, and IR and Raman spectroscopy). In addition, the solid-state structures of the compounds were confirmed by low-temperature X-ray analysis. (Compound 2: triclinic; space group P-1; a=5.997(1) A, b=8.714(1) A, c=13.830(2) A; α=107.35(1)°, β=90.53(1)°, γ=103.33(1)°; VUC=668.9(2) A3; Z=4; ρcalc=1.292 cm-3. Compound 3: monoclinic; space group P21/c; a=5.840(2) A, b=7.414(3) A, c=8.061(2) A; β=100.75(3) °; VUC=342(2) A3; Z=2; ρcalc=1. 396 g cm-3.) The vibrational frequencies of compounds 2 and 3 were calculated using the B3LYP method with a 6-311+G(d,p) basis set. We also computed the natural bond orbital (NBO) charges using the rMP2/aug-cc-pVDZ method and the heats of formation were determined on the basis of their electronic energies. Furthermore, the thermal stabilities of these compounds, as well as their sensitivity towards classical stimuli, were also assessed by differential scanning calorimetry and standard BAM tests, respectively. Lastly, the attempted synthesis of (E)-1,2,3,4-tetraformyl-2-tetrazene (6) is also discussed.
- Delalu, Henri,Sabate, Carlos Miro
-
experimental part
p. 715 - 724
(2012/07/03)
-
- A one-pot process for the regioselective synthesis of 1,3,4-trisubstituted-1H-pyrazoles
-
This Letter reports a facile and regioselective one-pot synthesis of 1,3,4-trisubstituted-1H-pyrazoles. It comprises a three-step telescoped sequence, which has been utilised in the production of a variety of differentially substituted pyrazoles.
- Raw, Steven A.,Turner, Andrew T.
-
experimental part
p. 696 - 699
(2011/02/27)
-
- Process for the manufacture of a tricyclic compound
-
A process for preparing a compound of formula (I) or a phamaceutically-acceptable salt thereof, comprising: 1) reacting a compound. of formula (III), in which R is a straight or branched chain alkyl having from one to four carbon atoms, with an alkali metal hydroxide in an aqueous medium at a temperature of about 80° to 120° C. and time of about 20 to 100 hours to form a reaction product; 2) cyclizing the reaction product of step 1) with formic acid and formaldehyde to form a formiate compound; and 3) neutralizing the formiate compound of step 2) with an aqueous base.
- -
-
-
